These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 29350470)

  • 1. Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy.
    Witt DA; Donson AM; Amani V; Moreira DC; Sanford B; Hoffman LM; Handler MH; Levy JMM; Jones KL; Nellan A; Foreman NK; Griesinger AM
    Pediatr Blood Cancer; 2018 May; 65(5):e26960. PubMed ID: 29350470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological evaluation of PD-L1 expression and cytotoxic T-lymphocyte infiltrates across intracranial molecular subgroups of ependymomas: are these tumors potential candidates for immune check-point blockade?
    Nambirajan A; Malgulwar PB; Sharma A; Boorgula MT; Doddamani R; Singh M; Suri V; Sarkar C; Sharma MC
    Brain Tumor Pathol; 2019 Oct; 36(4):152-161. PubMed ID: 31388782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma.
    Nowak J; Jünger ST; Huflage H; Seidel C; Hohm A; Vandergrift LA; von Hoff K; Rutkowski S; Pietsch T; Warmuth-Metz M
    Clin Neuroradiol; 2019 Dec; 29(4):595-604. PubMed ID: 30027327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Supratentorial non-RELA, ZFTA-fused ependymomas: a comprehensive phenotype genotype correlation highlighting the number of zinc fingers in ZFTA-NCOA1/2 fusions.
    Tauziède-Espariat A; Siegfried A; Nicaise Y; Kergrohen T; Sievers P; Vasiljevic A; Roux A; Dezamis E; Benevello C; Machet MC; Michalak S; Puiseux C; Llamas-Gutierrez F; Leblond P; Bourdeaut F; Grill J; Dufour C; Guerrini-Rousseau L; Abbou S; Dangouloff-Ros V; Boddaert N; Saffroy R; Hasty L; Wahler E; Pagès M; Andreiuolo F; Lechapt E; Chrétien F; Blauwblomme T; Beccaria K; Pallud J; Puget S; Uro-Coste E; Varlet P;
    Acta Neuropathol Commun; 2021 Aug; 9(1):135. PubMed ID: 34389065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma.
    Nam SJ; Kim YH; Park JE; Ra YS; Khang SK; Cho YH; Kim JH; Sung CO
    Cancer Immunol Immunother; 2019 Feb; 68(2):305-318. PubMed ID: 30483834
    [TBL] [Abstract][Full Text] [Related]  

  • 6. L1CAM Immunopositivity in Anaplastic Supratentorial Ependymomas: Correlation With Clinical and Histological Parameters.
    Chavali P; Rao S; Palavalasa S; Bevinahalli N; Muthane YTC; Sadashiva N; Santosh V
    Int J Surg Pathol; 2019 May; 27(3):251-258. PubMed ID: 30251576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. C11orf95-RELA fusions and upregulated NF-KB signalling characterise a subset of aggressive supratentorial ependymomas that express L1CAM and nestin.
    Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Rajeshwari M; Singh M; Suri V; Sarkar C; Sharma MC
    J Neurooncol; 2018 May; 138(1):29-39. PubMed ID: 29354850
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel type of C11orf95-LOC-RELA fusion in a grade II supratentorial ependymoma: report of a case with literature review.
    de Sousa GR; Marie SKN; Oba-Shinjo SM; Ramalho LNZ; Tone LG; Valera ET
    Childs Nerv Syst; 2019 Apr; 35(4):689-694. PubMed ID: 30631904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C11orf95-RELA reprograms 3D epigenome in supratentorial ependymoma.
    Zhu JJ; Jillette N; Li XN; Cheng AW; Lau CC
    Acta Neuropathol; 2020 Dec; 140(6):951-960. PubMed ID: 32909151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors.
    Fukuoka K; Kanemura Y; Shofuda T; Fukushima S; Yamashita S; Narushima D; Kato M; Honda-Kitahara M; Ichikawa H; Kohno T; Sasaki A; Hirato J; Hirose T; Komori T; Satomi K; Yoshida A; Yamasaki K; Nakano Y; Takada A; Nakamura T; Takami H; Matsushita Y; Suzuki T; Nakamura H; Makino K; Sonoda Y; Saito R; Tominaga T; Matsusaka Y; Kobayashi K; Nagane M; Furuta T; Nakada M; Narita Y; Hirose Y; Ohba S; Wada A; Shimizu K; Kurozumi K; Date I; Fukai J; Miyairi Y; Kagawa N; Kawamura A; Yoshida M; Nishida N; Wataya T; Yamaoka M; Tsuyuguchi N; Uda T; Takahashi M; Nakano Y; Akai T; Izumoto S; Nonaka M; Yoshifuji K; Kodama Y; Mano M; Ozawa T; Ramaswamy V; Taylor MD; Ushijima T; Shibui S; Yamasaki M; Arai H; Sakamoto H; Nishikawa R; Ichimura K;
    Acta Neuropathol Commun; 2018 Dec; 6(1):134. PubMed ID: 30514397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population.
    Hwang K; Koh EJ; Choi EJ; Kang TH; Han JH; Choe G; Park SH; Yearley JH; Annamalai L; Blumenschein W; Sathe M; McClanahan T; Jung H; Wang KC; Kim SK; Kim CY
    J Neurooncol; 2018 Sep; 139(2):281-291. PubMed ID: 29730815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of clinical factors and immunocheckpoint molecules in the prognosis of patients with supratentorial extraventricular ependymoma: a single-center retrospective study.
    Wang L; Han S; Yan C; Yang Y; Li Z; Yang Z
    J Cancer Res Clin Oncol; 2021 Apr; 147(4):1259-1270. PubMed ID: 33387039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging.
    Pagès M; Pajtler KW; Puget S; Castel D; Boddaert N; Tauziède-Espariat A; Picot S; Debily MA; Kool M; Capper D; Sainte-Rose C; Chrétien F; Pfister SM; Pietsch T; Grill J; Varlet P; Andreiuolo F
    Brain Pathol; 2019 May; 29(3):325-335. PubMed ID: 30325077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Notch pathway in ependymoma RELA-fused subgroup: upregulation and association with cancer stem cells markers expression.
    de Almeida Magalhães T; Cruzeiro GAV; de Sousa GR; da Silva KR; Lira RCP; Scrideli CA; Tone LG; Valera ET; Borges KS
    Cancer Gene Ther; 2020 Jun; 27(6):509-512. PubMed ID: 31308481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Supratentorial ependymoma in childhood: more than just RELA or YAP.
    Zschernack V; Jünger ST; Mynarek M; Rutkowski S; Garre ML; Ebinger M; Neu M; Faber J; Erdlenbruch B; Claviez A; Bielack S; Brozou T; Frühwald MC; Dörner E; Dreschmann V; Stock A; Solymosi L; Hench J; Frank S; Vokuhl C; Waha A; Andreiuolo F; Pietsch T
    Acta Neuropathol; 2021 Mar; 141(3):455-466. PubMed ID: 33481105
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Immunohistochemistry in the Identification of Supratentorial C11ORF95-RELA Fused Ependymoma in Routine Neuropathology.
    Gessi M; Giagnacovo M; Modena P; Elefante G; Gianno F; Buttarelli FR; Arcella A; Donofrio V; Diomedi Camassei F; Nozza P; Morra I; Massimino M; Pollo B; Giangaspero F; Antonelli M
    Am J Surg Pathol; 2019 Jan; 43(1):56-63. PubMed ID: 29266023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ependymoma-like tumor with mesenchymal differentiation harboring C11orf95-NCOA1/2 or -RELA fusion: A hitherto unclassified tumor related to ependymoma.
    Tomomasa R; Arai Y; Kawabata-Iwakawa R; Fukuoka K; Nakano Y; Hama N; Nakata S; Suzuki N; Ishi Y; Tanaka S; Takahashi JA; Yuba Y; Shiota M; Natsume A; Kurimoto M; Shiba Y; Aoki M; Nabeshima K; Enomoto T; Inoue T; Fujimura J; Kondo A; Yao T; Okura N; Hirose T; Sasaki A; Nishiyama M; Ichimura K; Shibata T; Hirato J; Yokoo H; Nobusawa S
    Brain Pathol; 2021 May; 31(3):e12943. PubMed ID: 33576087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RELA Fusion in Supratentorial Extraventricular Ependymomas: A Morphologic, Immunohistochemical, and Molecular Study of 43 Cases.
    Wang L; Liu L; Li H; Wang P; Hu Z; Wei Y; Zhang M; Wen W; Li Z; Liu L; Zhao L; Lu D; Teng L
    Am J Surg Pathol; 2019 Dec; 43(12):1674-1681. PubMed ID: 31393268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma.
    Tzaridis T; Milde T; Pajtler KW; Bender S; Jones DT; Müller S; Wittmann A; Schlotter M; Kulozik AE; Lichter P; Peter Collins V; Witt O; Kool M; Korshunov A; Pfister SM; Witt H
    Oncotarget; 2016 Sep; 7(38):61860-61873. PubMed ID: 27556362
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of ependymomas: assessment of consensus in pathological diagnosis and correlations with genetic profiles and outcome.
    Sasaki A; Hirato J; Hirose T; Fukuoka K; Kanemura Y; Hashimoto N; Kodama Y; Ichimura K; Sakamoto H; Nishikawa R
    Brain Tumor Pathol; 2019 Apr; 36(2):92-101. PubMed ID: 30929114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.